FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin

Article Link: FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin

Friday, June 28, 2019 – Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved Zirabev (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab),1 for the treatment of five types…

Source: FDA New Drug Approvals